Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Incidence of ESR1 gene mutations among patients with endometrioid endometrial cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society - 1 Feb 2026

Jang Minyoung, Dagher Christian, Gysler Stefan, Ko Emily M, Giuntoli Robert L, Martin Lainie, Kim Sarah H, Nasioudis Dimitrios

Abstract excerpt

Endometrioid endometrial cancer especially low-grade expresses estrogen receptors. A sub-group of patients derives significant benefit from hormonal treatment. The presence of activating ESR1 gene mutations is a common mechanism of resistance to hormonal treatment for patients with breast cancer. We evaluated the incidence of ESR1-activating gene mutations in patients with endometrioid endometrial cancer using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Endometrioid

Share to Class I Phosphatidylinositol 3-Kinases

Share to Endometrial Neoplasms

Share to Estrogen Receptor alpha

Share to Incidence

Share to Mutation

Source

Identifiers

PMID: 41435653
DOI: 10.1016/j.ijgc.2025.102816

Genes

ESR1
PIK3CA
AKT1
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Incidence of ESR1 gene mutations among patients with endometrioid endometrial cancer.PMID 41435653Read ↗

ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial.Semantic proximity Read ↗

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.Semantic proximity Read ↗

Characterization of ESR1 alterations in patients with breast and gynecologic cancers.Semantic proximity Read ↗

Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations.Semantic proximity Read ↗

ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment.Semantic proximity Read ↗

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.Semantic proximity Read ↗

ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.Semantic proximity Read ↗

Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma.Semantic proximity Read ↗

Estrogen receptor mutations and their role in breast cancer progression.Semantic proximity Read ↗

Prevalence of Estrogen Receptor Alpha (ESR1) Somatic Mutations in Breast Cancer.Semantic proximity Read ↗

ESR1 genetic alterations and their association with clinicopathologic characteristics in advanced breast cancer: a single academic institution experience.Semantic proximity Read ↗

Molecular Characterization of ESR1 Variants in Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.